Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.51 |
| ▸ | PDK1 | Q15118 | 5/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.34 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16768023 | 0.85 | HRH3 (0.53) | HRH3PDK1CCR2KCNH2NPSR1 | |
| SCHEMBL17014690 | 0.85 | PDK1 (0.58) | HRH3PDK1CCR2KCNH2NPSR1 | |
| SCHEMBL16768128 | 0.83 | HRH3 (0.51) | HRH3PDK1CCR2KCNH2NPSR1 | |
| SCHEMBL16768026 | 0.82 | HRH3 (0.50) | HRH3PDK1CCR2KCNH2NPSR1 | |
| SCHEMBL16770006 | 0.81 | PDK1 (0.46) | HRH3PDK1LMNAPOLBALDH1A1 | |
| SCHEMBL16767981 | 0.81 | HRH3 (0.49) | HRH3PDK1CCR2KCNH2NPSR1 | |
| SCHEMBL12110179 | 0.78 | HRH3 (0.48) | HRH3PDK1CCR2KCNH2P2RX3 | |
| SCHEMBL24477442 | 0.77 | HRH3 (0.60) | HRH3PDK1CCR2KCNH2 | |
| SCHEMBL26723897 | 0.77 | HRH3 (0.51) | HRH3PDK1CCR2KCNH2NPSR1 | |
| SCHEMBL20179866 | 0.77 | HRH3 (0.54) | HRH3PDK1CCR2KCNH2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340538-B2 | Dihydropyrimidine compounds and their application in pharmaceuticals | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-05-17 | — | — | US | disclosed |
| US-20150152096-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152096-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | DPYD, SLC10A1, HPRT1 | HRH3 1555/4885PDK1 601/4885CCR2 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.